Merck joins Pizer and Novartis in reducing drug prices
July 20, 2018Medical Communications Merck, Novartis, Pfizer, Trump, Twitter, price hikes
Merck & Co. have joined Pfizer and Novartis in halting price increases on medicines in the United States. The American …
Donald Trump thanks Novartis for halting price hikes
July 20, 2018Medical Communications Novartis, Pfizer, Trump, Twitter, price hikes
Donald Trump has thanked Swiss multinational Novartis for halting price hikes on prescription drugs in the United States. The US …
Novartis buys eczema drug in €95m deal
July 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, deal, eczema, experimental, patent
Novartis has agreed to buy the rights for a novel antibody MOR106 from the Belgo-Dutch pharmaceutical research company Galapagos and …
PhRMA take on PBM’s in response to Trump drug price plan
July 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
In response to Donald Trump’s plan to lower drug prices in the US, the Pharmaceutical Research and Manufacturers of America …
MPs vote to stay in EMA after Brexit
July 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, UK, brexit, parliament, vote
British MPs have voted for the UK’s continued participation in the regulatory network operated by the European Medicines Agency (EMA) …
Bill Gates commits $30m towards Alzheimer’s diagnostic test
July 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Bill Gates, billionaire, diagnosis
Microsoft business magnate Bill Gates has joined a coalition of philanthropists in committing more than $30 million towards the development …
Janssen’s Symtuza scores approval with the FDA in HIV-1
July 18, 2018Sales and Marketing HIV, Janssen, Symtuza, pharma
Janssen has announced that Symtuza (D/C/F/TAF) has received approval from the FDA in the treatment of human immunodeficiency virus type …
AstraZeneca increases drug stockpile in preparation for no-deal Brexit
July 18, 2018Research and Development AstraZeneca, brexit, no-deal, pharma, stockpiling
The Anglo-Swedish drug giant AstraZeneca is set to increase its stockpile of drugs in both the United Kingdom and the …
Novartis follows Pfizer’s lead, pledges no price hikes in 2018
July 18, 2018Research and Development, Sales and Marketing Novartis, Pfizer, President trump, Trump, US, pharma
Following US pharma giant Pfizer’s clash with President Donald Trump after it was called out on Twitter for hiking the …
Researchers develop algorithm able to identify antidepressant suitability
July 18, 2018Research and Development McLean, algorithm, antidepressants, research
A study published by researchers at McLean Hospital in Belmont, Massachusetts has led to the development of a statistical algorithm …
AbbVie and Mylan reach US marketing agreement for Humira biosimilar
July 18, 2018Research and Development, Sales and Marketing AbbVie, Humira, Mylan, US, pharma
AbbVie and Mylan have announced that they have both signed a licensing agreement for the former’s proposed biosimilar version of …
Renowned cancer researcher leaves ICR over bullying allegations
July 17, 2018Research and Development
Leading geneticist and cancer researcher, Nazneen Rahman CBE, has resigned from her position as head of Genetics and Epidemiology at …
Silence Therapeutics appoints ex-Akari CEO in top position
July 17, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Akari, CEO, Sanofi, Silence Therapeutics, zealand
Silence Therapeutics has appointed Dr David Horn Solomon as its new Chief Executive Officer (CEO), effective immediately. Solomon will head …
Researchers successfully minimise diabetes drug side-effects in animal models
July 17, 2018Manufacturing and Production, Research and Development FDA, diabetes, pharma, type 2 diabetes
Researchers at the University of Pennsylvania and Syracuse University have modified a key ingredient of current diabetes drugs to produce …
Roche flu drug proves efficacy at Phase 3, but enough to beat Tamiflu generics?
July 17, 2018Manufacturing and Production, Research and Development Roche, Tamiflu, baloxavir marboxil, flu, influenza, pharma
Roche is celebrating the news that its investigational influenza drug baloxavir marboxil performed well at Phase 3, meeting its primary …
J&J stops Invokana trial early after success in kidney disease and type 2 diabetes
July 17, 2018Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes
Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …
FDA cautions consumers on fake warning letter scam
July 17, 2018Manufacturing and Production FDA, fake, letter, scam, warning
The FDA has warned that criminals have been targeting customers who bought medicines online or over the phone with “official-looking, …
CRISPR gene editing may frequently cause undetected genetic damage
July 17, 2018Manufacturing and Production DNA, crispr, gene editing, genetic damage
Scientists studying the gene editing technology CRISPR-Cas9 have discovered the technique appears to frequently cause genetic damage that may slip …
Senate claims Novartis misled public on Trump lawyer deal
July 16, 2018Sales and Marketing Novartis, Senate, Trump, United States, deal
A report released by the United States Senate has found that Novartis’ relationship with Donald Trump’s long-time lawyer Michael Cohen …
Recruitment and retention: How can we do better?
July 16, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, feature, patient recruitment, patients, pharma
In pharma R&D, data is king, but consistent struggles with patient retention is undermining the integrity of clinical findings. Matt …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
